Hydroximic acid derivatives, pharmaceutical compositions containing
them, and processes for preparing the same
    7.
    发明授权
    Hydroximic acid derivatives, pharmaceutical compositions containing them, and processes for preparing the same 失效
    含羟基酸衍生物,含有它们的药物组合物及其制备方法

    公开(公告)号:US5919796A

    公开(公告)日:1999-07-06

    申请号:US737168

    申请日:1996-11-05

    摘要: Hydroximic acid derivatives possess anti-ischemic effects, and therefore, they are useful for treating ischemic states and diseases, such as myocardial ischemia (which may be induced by occlusion of coronary arteries). These derivatives include compounds of formula (I): ##STR1## wherein: X represents a halogen; Z represents an aromatic group, a pyridinyl group, a picolyl group, or a lutidyl group; and R represents an --A--N(R.sub.1)R.sub.2 group, wherein:R.sub.1 and R.sub.2 represent, independently from each other, hydrogen or an alkyl group;or R.sub.1 and R.sub.2, together with the adjacent nitrogen atom, form a 5- to 7-membered,saturated heterocyclic group optionally containing an additional nitrogen, oxygen,or sulfur atom, the heterocyclic group optionally being substituted by at least one alkyl group; andA represents a straight or branched chain alkylene group, as well as pharmaceutically acceptable acid addition salts thereof. The invention further relates to processes for preparing the above noted compounds, and pharmaceutical compositions containing these compounds or their pharmaceutically acceptable acid addition salts as an active ingredient. Additionally, the invention relates to intermediate compounds of formula II used in preparing the compounds of formula I. Formula II is as follows: ##STR2## In formula II, the variables Z and R have the same definitions provided above.

    摘要翻译: PCT No.PCT / HU95 / 00014 Sec。 371日期:1996年11月5日 102(e)日期1996年11月5日PCT提交1995年5月4日PCT公布。 公开号WO95 / 30649 日期1995年11月16日海洛因衍生物具有抗缺血作用,因此它们可用于治疗缺血状态和疾病,例如心肌缺血(其可能由冠状动脉闭塞引起)。 这些衍生物包括式(I)的化合物:其中:X表示卤素; Z表示芳基,吡啶基,吡啶甲基或联脂基; 并且R表示-A-N(R1)R2基团,其中:R1和R2彼此独立地表示氢或烷基; 或R 1和R 2与相邻的氮原子一起形成任选地含有另外的氮,氧或硫原子的5至7元饱和杂环基,所述杂环基任选被至少一个烷基取代; A表示直链或支链亚烷基,以及其药学上可接受的酸加成盐。 本发明还涉及制备上述化合物的方法和含有这些化合物或其药学上可接受的酸加成盐作为活性成分的药物组合物。 此外,本发明涉及用于制备式I化合物的式II的中间体化合物。式II如下:在式II中,变量Z和R具有与上述相同的定义。

    Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions
    8.
    发明授权
    Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions 失效
    抗缺血性羟胺衍生物和药物组合物

    公开(公告)号:US6002002A

    公开(公告)日:1999-12-14

    申请号:US914115

    申请日:1998-05-13

    摘要: The present invention provides novel hydroxylamine derivatives represented by the general formula: wherein:X is O, --NH, or a group of formula NR', wherein R and R' are independently selected from alkyl, cycloalkyl, phenylalkyl, phenyl optionally substituted with halo, haloalkyl,alkyl, alkoxy or nitro; and a N-containing heterocyclic ring;R.sup.1 is H or alkanoyl,R.sup.2 is H or hydroxy optionally acylated with alkanoyl, andR.sup.3 is a group of the formula --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 are independently selected fromH, alkyl, and a group of the formula --CO--NH--R wherein R is as defined above, orwherein R.sup.4 and R.sup.5 when taken together form a 5- to 7-membered heterocyclic ring which may optionally contain one additional hetero atom selected from nitrogen, oxygen and sulfur and which is optionally substituted with alkyl or phenylalkyl.Also provided are pharmaceutically acceptable acid addition salts of the compounds defined above, as well as pharmaceutical compositions containing the compounds or their acid addition salts as active ingredients. The compounds of the invention have been shown to have anti-ischemic effects.

    摘要翻译: PCT No.PCT / HU96 / 00033 Sec。 371日期1998年5月13日 102(e)1998年5月13日PCT PCT 1996年6月14日PCT公布。 出版物WO97 / 00251 日本1997年1月3日本发明提供由以下通式表示的新型羟胺衍生物:其中:X为O,-NH或式NR'基团,其中R和R'独立地选自烷基,环烷基,苯基烷基, 任选被卤素,卤代烷基,烷基,烷氧基或硝基取代的苯基; 和含N的杂环; R1是H或烷酰基,R2是H或羟基,任选地被烷酰基酰化,R3是式-NR4R5的基团,其中R4和R5独立地选自H,烷基和式-CO-NH-R的基团 其中R如上所定义,或者其中R 4和R 5一起形成5至7元杂环,其可以任选地含有一个选自氮,氧和硫的另外的杂原子,并且其任选被烷基或苯基烷基取代。 还提供了上述化合物的药学上可接受的酸加成盐,以及含有化合物或其酸加成盐作为活性成分的药物组合物。 已经显示本发明的化合物具有抗缺血作用。